{"id":"NCT00737672","sponsor":"W.L.Gore & Associates","briefTitle":"GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis","officialTitle":"GORE VIABAHN® Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2011-05","completion":"2013-06","firstPosted":"2008-08-19","resultsPosted":"2014-10-21","lastUpdate":"2014-10-21"},"enrollment":293,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Failure","Hemodialysis"],"interventions":[{"type":"DEVICE","name":"GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface","otherNames":[]},{"type":"PROCEDURE","name":"Percutaneous Transluminal Angioplasty","otherNames":[]}],"arms":[{"label":"VIABAHN Treatment Group","type":"EXPERIMENTAL"},{"label":"PTA Treatment Group","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis.","primaryOutcome":{"measure":"Target Lesion Primary Patency at 6 Months","timeFrame":"6 months","effectByArm":[{"arm":"VIABAHN Treatment Group","deltaMin":52.9,"sd":null},{"arm":"PTA Treatment Group","deltaMin":35.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":["30717951"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":78,"n":145},"commonTop":["Chest pain"]}}